Evidence map›Paper›PMID 41154657›Full record

ReviewBiomolecules2025

Targeting CRABP1 Signalosomes in Managing Neurodegeneration.

Jennifer Nhieu, Li-Na Wei

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jennifer NhieuDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0002-2448-6127
Li-Na WeiDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0002-6376-8506

Funding

TR2 NUCLEAR RECEPTOR IN VITAMIN A SIGNALING PATHWAYSR01DK054733 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI WEI, LI-NA · 1999 to 2021
$5.7M
TR2 nuclear receptor in vitamin A signalingR01NS132277 · NINDS · UNIVERSITY OF MINNESOTA · PI Li-Na Wei · 2023 to 2026
$1.9M
National Institute of Health R01NS132277NIDDK NIH HHS R01 DK054733NINDS NIH HHS R01 NS132277
6 · The paper itself

Abstract

Retinoic acid (RA) binds RA (RAR) and Retinoid X (RXR) receptors to elicit biological effects by regulating transcription. RA is also known to have non-canonical activities mediated, primarily, by cellular retinoic acid-binding protein 1 (CRABP1) which forms protein complexes named "CRABP1 signalosomes" to regulate cytosolic signaling independent of RARs/RXRs. This review focuses on therapeutic applications in neurodegeneration by targeting CRABP1 signalosomes including CRABP1-MAPK, CRABP1-CaMKII, CRABP1-eIF2α, and others recently identified from our proteomic studies. The mouse

Indexed as

Neurodegenerative DiseasesReceptors, Retinoic AcidAnimalsHumansSignal TransductionTretinoinReceptors, Retinoic Acidretinoic acid binding protein I, cellularTretinoinADALSatRACRABP1HDneurodegenerationnon-canonical activityPD

Identifiers

PMID41154657
PMCPMC12562481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.